Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial | Zendy

Ward Fickweiler | Zendy; Ingeborg Klaassen | Zendy; Ilse M. C. Vogels | Zendy; Johanna M. M. Hooymans | Zendy; Bruce H. R. Wolffenbuttel | Zendy; Leonoor I. Los | Zendy; Reinier O. Schlingemann | Zendy

Open Access

Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial

Author(s) -

Ward Fickweiler,

Ingeborg Klaassen,

Ilse M. C. Vogels,

Johanna M. M. Hooymans,

Bruce H. R. Wolffenbuttel,

Leonoor I. Los,

Reinier O. Schlingemann

Publication year - 2016

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.16-20157

Subject(s) - medicine , ranibizumab , ophthalmology , visual acuity , bevacizumab , diabetic retinopathy , vascular endothelial growth factor , endocrinology , diabetes mellitus , vegf receptors , chemotherapy

The purpose of this study was to evaluate selected candidate biomarkers as potential markers for patients with diabetic macular edema (DME) who receive antivascular endothelial growth factor (VEGF) therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research